Work

A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps3165

Authors: George R. Blumenschein, Diwakar Davar, Rodolfo Gutierrez, Neil Howard Segal, Melissa Lynne Johnson, Mohammed M. Dar, Shannon Marshall

Institutions: The University of Texas MD Anderson Cancer Center, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Angeles Clinic and Research Institute, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Sarah Cannon

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3029402008

Cites:

Cited by: 10

Related to: 10